BREAKING: FDA Rejects Lykos Therapeutics’ MDMA-Assisted Therapy For PTSD Post published:August 9, 2024 Post category:Analysis/News
Vibe Check: FDA Set to Decide Future of MDMA-Assisted Therapy This Week Post published:August 6, 2024 Post category:Analysis/News
Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking Post published:July 16, 2024 Post category:Analysis/News/Pα+
Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD Post published:July 9, 2024 Post category:Analysis/News/Pα+
In Brief: ICER Issues Final Evidence Report and Recommendations Re: MDMA-Assisted Therapy; Lykos Responds Post published:June 27, 2024 Post category:Analysis/News
No NHS Coverage for Janssen’s Spravato: NICE Denies Re-Appraisal of Esketamine for TRD Post published:June 21, 2024 Post category:Analysis/News/Pα+
Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals Post published:June 13, 2024 Post category:Analysis/News
Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote Post published:June 11, 2024 Post category:Analysis/News/Pα+
Live Coverage: FDA Advisory Committee Reviews MDMA-Assisted Therapy for PTSD Post published:June 4, 2024 Post category:Analysis/News